Combination therapy for hypertension: focus on high-dose olmesartan medoxomil (40 mg) plus hydrochlorothiazide

Bibliography

• Kearney PM, Whelton M, Reynolds K, Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-23
   PubMed Web of Science ®Google Scholar
• Ezzati M, Lopez AD, Rodgers A, Selected major risk factors and global and regional burden of disease. Lancet 2002;360:1347-60
   PubMed Web of Science ®Google Scholar
• Lewington S, Clarke R, Qizilbash N, Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13
   PubMed Web of Science ®Google Scholar
• Padwal R, Straus SE, McAlister FA. Evidence based management of hypertension. Cardiovascular risk factors and their effects on the decision to treat hypertension: evidence based review. BMJ 2001;322:977-80
   PubMed Web of Science ®Google Scholar
• Thorp ML, Eastman L, Smith DH, Johnson ES. Managing the burden of chronic kidney disease. Dis Manag 2006;9:115-21
   PubMedGoogle Scholar
• Kopyt NP. Slowing progression along the renal disease continuum. J Am Osteopath Assoc 2005;105:207-15
   PubMedGoogle Scholar
• Mancia G, De Backer G, Dominiczak A, 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87
   PubMed Web of Science ®Google Scholar
• Mancia G, Laurent S, Agabiti-Rosei E, Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009;27:2121-58
   PubMed Web of Science ®Google Scholar
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97
   PubMed Web of Science ®Google Scholar
• Materson BJ, Reda DJ, Cushman WC, Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993;328:914-21
   PubMed Web of Science ®Google Scholar
• Philipp T, Anlauf M, Distler A, Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE study. HANE Trial Research Group. BMJ 1997;315:154-9
   PubMed Web of Science ®Google Scholar
• Dahlof B, Devereux RB, Kjeldsen SE, Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003
   PubMed Web of Science ®Google Scholar
• Beckett NS, Peters R, Fletcher AE, Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358:1887-98
   PubMed Web of Science ®Google Scholar
• Dahlof B, Sever PS, Poulter NR, Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906
   PubMed Web of Science ®Google Scholar
• Patel A, MacMahon S, Chalmers J, Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370:829-40
   PubMed Web of Science ®Google Scholar
• Jamerson K, Weber MA, Bakris GL, Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-28
   PubMed Web of Science ®Google Scholar
• Wald DS, Law M, Morris JK, Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009;122:290-300
   PubMed Web of Science ®Google Scholar
• Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120:713-19
   PubMed Web of Science ®Google Scholar
• Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010;55:399-407
   PubMed Web of Science ®Google Scholar
• Bangalore S, Parkar S, Grossman E, Messerli FH. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol 2007;100:1254-62
   PubMed Web of Science ®Google Scholar
• Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007;369:201-7
   PubMed Web of Science ®Google Scholar
• Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens 2006;24:3-10
   PubMed Web of Science ®Google Scholar
• Yusuf S, Teo KK, Pogue J, Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59
   PubMed Web of Science ®Google Scholar
• Mann JF, Schmieder RE, McQueen M, Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008;372:547-53
   PubMed Web of Science ®Google Scholar
• Kjeldsen SE, Os I, Hoieggen A, Fixed-dose combinations in the management of hypertension: defining the place of angiotensin receptor antagonists and hydrochlorothiazide. Am J Cardiovasc Drugs 2005;5:17-22
   PubMedGoogle Scholar
• Hoieggen A, Alderman MH, Kjeldsen SE, The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004;65:1041-9
   PubMed Web of Science ®Google Scholar
• Lindholm LH, Ibsen H, Dahlof B, Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004-10
   PubMed Web of Science ®Google Scholar
• Lindholm LH, Persson M, Alaupovic P, Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003;21:1563-74
   PubMed Web of Science ®Google Scholar
• Conlin PR, Spence JD, Williams B, Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2000;13:418-26
   PubMed Web of Science ®Google Scholar
• Neutel JM, Franklin SS, Lapuerta P, A comparison of the efficacy and safety of irbesartan/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension. J Hum Hypertens 2008;22:266-74
   PubMed Web of Science ®Google Scholar
• Ohman KP, Milon H, Valnes K. Efficacy and tolerability of a combination tablet of candesartan cilexetil and hydrochlorothiazide in insufficiently controlled primary hypertension – comparison with a combination of losartan and hydrochlorothiazide. Blood Press 2000;9:214-20
   PubMed Web of Science ®Google Scholar
• Plosker GL, White WB. Telmisartan/hydrochlorothiazide: a review of its use as fixed-dose combinations in essential hypertension. Drugs 2008;68:1877-99
   PubMed Web of Science ®Google Scholar
• Schmidt A, Adam SA, Kolloch R, Antihypertensive effects of valsartan/hydrochlorothiazide combination in essential hypertension. Blood Press 2001;10:230-7
   PubMed Web of Science ®Google Scholar
• Sellin L, Stegbauer J, Laeis P, Rump LC. Adding hydrochlorothiazide to olmesartan dose dependently improves 24-h blood pressure and response rates in mild-to-moderate hypertension. J Hypertens 2005;23:2083-92
   PubMed Web of Science ®Google Scholar
• Waeber B, Aschwanden R, Sadecky L, Ferber P. Combination of hydrochlorothiazide or benazepril with valsartan in hypertensive patients unresponsive to valsartan alone. J Hypertens 2001;19:2097-104
   PubMed Web of Science ®Google Scholar
• Wagstaff AJ. Valsartan/hydrochlorothiazide: a review of its use in the management of hypertension. Drugs 2006;66:1881-901
   PubMed Web of Science ®Google Scholar
• Le MT, Pugsley MK, Vauquelin G, Van Liefde I. Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor. Br J Pharmacol 2007;151:952-62
   PubMed Web of Science ®Google Scholar
• Barrios V, Boccanelli A, Ewald S, Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study. Clin Drug Investig 2007;27:545-58
   PubMed Web of Science ®Google Scholar
• Chrysant SG, Weber MA, Wang AC, Hinman DJ. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens 2004;17:252-9
   PubMed Web of Science ®Google Scholar
• Mallion JM, Heagerty A, Laeis P. Systolic blood pressure reduction with olmesartan medoxomil versus nitrendipine in elderly patients with isolated systolic hypertension. J Hypertens 2007;25:2168-77
   PubMed Web of Science ®Google Scholar
• Ball KJ, Williams PA, Stumpe KO. Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives. J Hypertens Suppl 2001;19:S49-56
   PubMedGoogle Scholar
• Rump LC, Ambrosioni E, Burnier M, Initial combination therapy with olmesartan/hydrochlorothiazide in moderate-to-severe hypertension. J Hum Hypertens 2006;20:299-301
   PubMed Web of Science ®Google Scholar
• Ram CV. Antihypertensive efficacy of angiotensin receptor blockers in combination with hydrochlorothiazide: a review of the factorial-design studies. J Clin Hypertens (Greenwich) 2004;6:569-77
   PubMedGoogle Scholar
• Jones MR, Sealey JE, Laragh JH. Effects of angiotensin receptor blockers on ambulatory plasma renin activity in healthy, normal subjects during unrestricted sodium intake. Am J Hypertens 2007;20:907-16
   PubMed Web of Science ®Google Scholar
• Izzo Jr JL, Neutel JM, Silfani T, Efficacy and safety of treating stage 2 systolic hypertension with olmesartan and olmesartan/HCTZ: results of an open-label titration study. J Clin Hypertens (Greenwich) 2007;9:36-44
   PubMedGoogle Scholar
• Izzo Jr JL, Neutel JM, Silfani T, Titration of HCTZ to 50 mg daily in individuals with stage 2 systolic hypertension pretreated with an angiotensin receptor blocker. J Clin Hypertens (Greenwich) 2007;9:45-8
   PubMedGoogle Scholar
• Kereiakes DJ, Neutel J, Stoakes KA, The effects of an olmesartan medoxomil-based treatment algorithm on 24-hour blood pressure levels in elderly patients aged 65 and older. J Clin Hypertens (Greenwich) 2009;11:411-21
   PubMed Web of Science ®Google Scholar
• Neutel JM, Kereiakes DJ, Waverczak WF, Effects of an olmesartan medoxomil based treatment algorithm on 24-hour blood pressure control in patients with hypertension and type 2 diabetes. Curr Med Res Opin 2010;26:721-8
   PubMed Web of Science ®Google Scholar
• Oparil S, Chrysant SG, Kereiakes D, Results of an olmesartan medoxomil-based treatment regimen in hypertensive patients. J Clin Hypertens (Greenwich) 2008;10:911-21
   PubMed Web of Science ®Google Scholar
• Oparil S, Pimenta E. Efficacy of an olmesartan medoxomil-based treatment algorithm in patients stratified by age, race, or sex. J Clin Hypertens (Greenwich) 2010;12:3-13
   PubMedGoogle Scholar
• Rump LC, Girerd X. Hydrochlorothiazide (HCTZ) provides additional blood pressure (BP)-lowering when used as an add-on therapy in patients with moderate-to-severe hypertension whose BP is not adequately controlled by olmesartan medoxomil (OM) 40 mg. J Hypertens 2009;27(Suppl 4):S282
   Google Scholar
• Fogari R. Phase III study evaluating the efficacy and safety of olmesartan medoxomil/hydrochlorothiazide 40/12.5 mg combination therapy versus olmesartan medoxomil 40 mg monotherapy in patients with essential hypertension. J Hypertens 2009;27(Suppl 4):S275
   PubMedGoogle Scholar
• EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001;22:554-72
   PubMed Web of Science ®Google Scholar
• Primatesta P, Brookes M, Poulter NR. Improved hypertension management and control: results from the health survey for England 1998. Hypertension 2001;38:827-32
   PubMed Web of Science ®Google Scholar
• Sachse A, Verboom CN, Jager B. Efficacy of eprosartan in combination with HCTZ in patients with essential hypertension. J Hum Hypertens 2002;16:169-76
   PubMed Web of Science ®Google Scholar
• Pool JL, Glazer R, Weinberger M, Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults. Clin Ther 2007;29:61-73
   PubMed Web of Science ®Google Scholar
• White WB, Murwin D, Chrysant SG, Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial. Blood Press Monit 2008;13:21-7
   PubMed Web of Science ®Google Scholar
• European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53
   PubMed Web of Science ®Google Scholar
• Izzo Jr JL, Levy D, Black HR. Clinical Advisory Statement. Importance of systolic blood pressure in older Americans. Hypertension 2000;35:1021-4
   PubMedGoogle Scholar
• Mancia G, Bombelli M, Lanzarotti A, Systolic vs diastolic blood pressure control in the hypertensive patients of the PAMELA population. Pressioni Arteriose Monitorate e Loro Associazioni. Arch Intern Med 2002;162:582-6
   PubMedGoogle Scholar
• Swales JD. Current clinical practice in hypertension: the EISBERG (Evaluation and Interventions for Systolic Blood pressure Elevation-Regional and Global) project. Am Heart J 1999;138:231-7
   PubMed Web of Science ®Google Scholar